Evidence map›Paper›PMID 42190649›Full record

ArticleImmunity2026

Dietary sulfur amino acids enhance anti-tumor immunity in colon cancer via an NKT cell-XCL1-cDC1 circuit.

Lior Lobel, Diogo Fonseca-Pereira, Geicho Nakatsu, Monia Michaud, Y Grace Cao, Sena Bae, Cathleen Krabak, Yaara Oren, Slater L Clay, Geniver El Tekle and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Lior LobelDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Diogo Fonseca-PereiraDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Geicho NakatsuDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Monia MichaudDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Y Grace CaoDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Sena BaeDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Cathleen KrabakDivision of Medical Sciences Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
Yaara OrenDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Slater L ClayDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Geniver El TekleDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Eunyoung ChunDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA.
Shigeyuki KonDepartment of Molecular Immunology, Faculty of Pharmaceutical Sciences, Fukuyama University, Hiroshima 729-0292, Japan.
Andrew T ChanDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
Jon ClardyDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Blavatnik Institute, Boston, MA 02115, USA.
Jonathan N GlickmanDivision of Gastrointestinal Pathology, Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
Nadim J AjamiPlatform for Innovative Microbiome and Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abderrahman DayPlatform for Innovative Microbiome and Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ashish DamaniaPlatform for Innovative Microbiome and Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Erez N BaruchDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael G WhitePlatform for Innovative Microbiome and Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Laurence P DiggsDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jennifer WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Thomas RiffelmacherLa Jolla Institute for Immunology, La Jolla, CA 92037, USA; Faculty of Medicine, University Hospital Cologne, Clinic III for Internal Medicine, University of Cologne, Cologne 50937, Germany.
Ann BalancioLa Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Mitchell KronenbergLa Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Molecular Biology, University of California, San Diego, La Jolla, CA 92093, USA.
Curtis HuttenhowerDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Wendy S GarrettDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Harvard T.H. Chan Microbiome in Public Health Center, Boston, MA 02115, USA; Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: wgarrett@hsph.harvard.edu.

Funding

Precision Prevention Research ProgramR35CA253185 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Andrew T Chan · 2020 to 2026
$6.9M
IgE antibody responses to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal) in murine and human atherosclerosisR01AI172112 · NIAID · UNIVERSITY OF VIRGINIA · PI Loren D Erickson, Coleen A McNamara · 2022 to 2026
$6.4M
Gut microbiota and inflammatory monocytes in colorectal cancerR01CA154426 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI GARRETT, WENDY S. · 2011 to 2025
$5.2M
Dietary sulfur, the gut microbiome, and colorectal cancerR01CA202704 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T, GARRETT, WENDY S. · 2016 to 2020
$2.8M
Training Program in Immunological Tolerance and AutoimmunityT32AI118692 · NIAID · HARVARD MEDICAL SCHOOL · PI PILLAI, SHIV SUBRAMANIAM · 2015 to 2019
$948k
Microbiota regulation of intestinal eosinophilsF31DK121375 · NIDDK · HARVARD MEDICAL SCHOOL · PI CAO, YIYUN GRACE · 2019 to 2022
$91k
NCI NIH HHS R01 CA154426NCI NIH HHS R01 CA202704NCI NIH HHS R35 CA253185NIAID NIH HHS R01 AI172112NIAID NIH HHS T32 AI118692NIDDK NIH HHS F31 DK121375
6 · The paper itself

Abstract

The efficacy of immune checkpoint inhibitors (ICIs) in colon cancer (CC) is limited by the tolerogenic immune landscape of both the tumor and the intestine. Here, we investigated the impact of microbial metabolic pathways associated with ICI responsiveness on anti-tumor immunity in CC. Sulfur amino acid (Saa) metabolic pathways were enriched in ICI responders and in individuals without CC. In murine models, high-Saa diets restricted CC progression, increased colonic mucus thickness, and promoted the expansion of mucus-dwelling Mucispirillum schaedleri (M. schaedleri). Dietary Saa supplementation increased the frequency of activated intratumoral cytotoxic CD8

Indexed as

Chemokines, CColonic NeoplasmsDendritic CellsNatural Killer T-CellsAnimalsDietHumansMiceMice, Inbred C57BLChemokines, Canti-tumor immunitycDC1colon cancermicrobiomeMucispirillum schaedlerimucusNKTsulfur amino acidsXCL1

Identifiers

PMID42190649
PMCPMC13245371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.